Cargando…
The Small-Molecule E26-Transformation-Specific Inhibitor TK216 Attenuates the Oncogenic Properties of Pediatric Leukemia
The E26-transformation-specific (ETS) transcription factors regulate multiple aspects of the normal hematopoietic system. There is an increasing body of evidence suggesting aberrant ETS activity and its contribution to leukemia initiation and progression. In this study, we evaluated the small-molecu...
Autores principales: | Sharma, Ritul, Zhang, Chunfen, Narendran, Aru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10606408/ https://www.ncbi.nlm.nih.gov/pubmed/37895265 http://dx.doi.org/10.3390/genes14101916 |
Ejemplares similares
-
TK216 targets microtubules in Ewing sarcoma cells
por: Povedano, Juan Manuel, et al.
Publicado: (2022) -
The HIV protease inhibitor, nelfinavir, as a novel therapeutic approach for the treatment of refractory pediatric leukemia
por: Meier-Stephenson, Vanessa, et al.
Publicado: (2017) -
Potent in vitro and xenograft antitumor activity of a novel agent, PV-10, against relapsed and refractory neuroblastoma
por: Swift, Lucy, et al.
Publicado: (2019) -
Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia
por: Brandao, L N, et al.
Publicado: (2013) -
Aurora Kinases as Druggable Targets in Pediatric Leukemia: Heterogeneity in Target Modulation Activities and Cytotoxicity by Diverse Novel Therapeutic Agents
por: Jayanthan, Aarthi, et al.
Publicado: (2014)